Agilent Technologies Inc. shares are up during Monday’s premarket session as the company announces the acquisition of Biocare ...

Agilent Technologies Inc. agreed to acquire privately held Biocare Medical, which makes instruments and materials used in ...

Biocare has been under the stewardship of VC firms Excellere Partners and GHO Capital since 2021, achieving revenue of $90m ...

Biocare’s strong growth in immunohistochemistry is expected to strengthen Agilent’s ability to develop new in vitro diagnostic antibodies.

By Sahil Pandey March 9 (Reuters) - Life sciences firm Agilent Technologies said on Monday that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal valued at ...

Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by ...

Agilent Technologies stock overview Agilent Technologies (A) has drawn investor attention after recent share performance, with the stock showing negative returns over the past month and past 3 months ...

Agilent Technologies said that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal of $950 million ...

Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions business, in an all-cash transaction valued at $950 million. | Bay Area ...

Agilent Technologies, Inc. (NYSE:A) is included among the 13 Best Income Stocks with Highest Upside Potential. On February 27, Goldman Sachs lowered its price recommendation on Agilent Technologies, ...

Agilent Technologies stock (NYSE: A), which provides instruments and consumables for laboratories, trades at $113 per share, 10% below the level seen in March 2021. Agilent’s stock was trading at ...

Agilent Technologies has agreed to buy pathology company Biocare Medical in an all-cash deal valued at $950 million that bolsters its immunohistochemistry offering.